This study explores a new drug, Depemokimab, for adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 inflammation. COPD is a lung disease causing breathing problems and Type 2 inflammation refers to a specific kind of immune response. Depemokimab is being tested to see if it helps people with moderate to severe COPD who have not found relief with other treatments. To join, you need to be between 40 and 80 years old, have a history of frequent COPD flare-ups, and be on specific inhaler medications for at least six months. You must also have a high blood eosinophil count, which is a type of white blood cell involved in inflammation.

• The study involves multiple visits and tests to track your health and response to the treatment.
• Participants need to have a history of smoking and should not have other lung diseases.
• Potential risks include common COPD symptoms and possible side effects from the medication.